Premium
Histamine‐induced wheal, flare, and pruritus: Inhibition by cetirizine, terfenadine, and placebo
Author(s) -
Coulie P. J.,
Ghys L.,
Rihoux J. P.
Publication year - 1991
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.430230309
Subject(s) - terfenadine , cetirizine , placebo , medicine , crossover study , pharmacology , histamine h1 receptor , hydroxyzine , histamine , volunteer , antagonist , alternative medicine , receptor , pathology , agronomy , biology
Twelve adult volunteers were enrolled in a four‐session, double‐blind, crossover, randomized study. On each session, two capsules were administered in the morning and contained the pulverised products of either placebo (P) + P, terfenadine (T) 60 (mg) +P, T 60 + T 60, or cetirizine (C) 10 + P. On the evening of each experimental day, two capsules were taken at 0800 pm either as P + P or as T 60 + P or as P + P, or as P + P. We thus have four groups called, respectively, placebo, terfenadine 60 bid, terfenadine 120, and cetirizine 10. Pricks (100 mg/ml histamine) were performed before drug intake and 5, 12, 17, and 24 hr after drug intake. Ten minutes after each prick, wheal areas were underlined and transfered onto a transparency to be measured later. One volunteer gave up the trial due to the appearance of a serious disease not related to the trial. Regarding initial wheals, cetirizine 10, terfenadine 60 bid, and terfenadine 120 significantly (P < 0.01) reduced the wheal at H5, H12, H17, and H24 (except NS at H17 for T120). At H5, H12, and H17, cetirizine 10, terfenadine 60 bid, and terfenadine 120 were significantly more potent than P (P < 0.03). At H24, only cetirizine 10 and terfenadine 60 bid were significantly more potent than placebo. Pairwise global comparison shows a significant difference (P = 0.03) in favour of cetirizine regarding terfenadine 120. Side effects under active drugs were not different from those under placebo.